Cardiac Insight’s Wearable ECG Sensor, Cardea SOLO™, Continues to Attract Premier Cardiology Groups Across the U.S.; Announces Baltimore Heart Associates and Regional Cardiac Arrhythmia as Customers
Company Experiencing Steady Sales Growth and Strong Repeat Orders from Existing Customers
Cardea SOLO Device and Automated Software Analysis System Speeds Time to Cardiac Arrhythmia Diagnosis, Enhances Patient Experience
KIRKLAND, Wash.--(BUSINESS WIRE)-- Cardiac Insight, Inc., a leading U.S. developer of wearable biosensors and diagnostic software systems featuring proprietary automated data analysis algorithms, announced today that its wearable ECG Sensor, Cardea SOLO, continues to attract high-volume cardiology group practices across the U.S. The company unveiled Baltimore Heart Associates of Maryland (www.baltimoreheart.com) and Regional Cardiac Arrhythmia of Pennsylvania and Ohio (www.regionalcardiac.com) as two of its newest multi-location practice customers. Cardiac Insight also announced the company is experiencing steady month-to-month sales growth and increases in repeat orders for Cardea SOLO in its targeted markets across the country.
Both cardiology groups selected Cardea SOLO for its unique ability to provide a higher standard of ambulatory cardiac care, improved operational and financial metrics for their practices, and positive patient experiences.
“Baltimore Heart Associates is recognized for its unique ability to provide the highest standard of patient care and operational efficiency while serving the greater Baltimore area with our seven cardiologists and three office locations. Our adoption of industry-first Cardea SOLO supports our mission to bring cutting-edge technology and quality-driven care to our patients,” said Mohammed Abuzahra, MD FACC. “Cardea SOLO is patient-friendly and an easy-to-use system. Once ordered by one of our prescribing clinicians, the device is applied to the patient and seven days later the patient returns to have the ECG data analyzed right in our office—it’s that simple.”
“Cardea SOLO brings a much needed ‘sea change’ to ambulatory arrhythmia detection,” added Maninder Bedi, MD, a clinical cardiac electrophysiologist with Regional Cardiac Arrhythmia of Washington, Pennsylvania. “Adoption was painless and Cardea SOLO’s design made it easy to integrate into our clinical workflow. Our patients love the comfort and freedom of the cable-free chest-worn form factor, and we enjoy the immediate access to complete ECG data whenever we want it. Our office controls the entire process so that we can offer the highest quality of service and patient care.”
“Cardiac Insight is experiencing outstanding momentum in all areas of the business, and our continued sales trajectory combined with growing reorders affirms that our technology solutions align with the needs of practitioners and their patients, as shown by the adoption from these prestigious institutions,” said Brad Harlow, Chief Executive Officer. “Our company and technology continue to raise the bar for frontline cardiac care, while helping to save lives and optimize healthcare operations. Our Cardea SOLO brings exclusive and proprietary capabilities to our customers that no other wearable cardiac monitoring technology can offer.”
Cardea SOLO is a wearable, light (weight of three quarters), wire-free, seven-day ECG Sensor that comes complete with a PC-based, in-office Analysis Software System for the detection of adult cardiac arrhythmias, including Atrial Fibrillation (AFib).
Cardiac Insight said Cardea SOLO can trim days or weeks off ECG report turnaround time compared to using third-party ECG reporting services. It is the only in-office PC-based ECG Analysis Software cleared by the U.S. Food and Drug Administration (FDA) to produce an automated draft summary report without human intervention. The report is ready for clinician review or edits in five minutes or less. Cardea SOLO Software also provides clinicians access to, and ownership of, every heartbeat of patient data for further analysis.
The Cardea SOLO System detects and analyzes a broad range of cardiac arrhythmias that can cause disability and even death if undiagnosed and untreated. Millions of adults across the United States and Europe suffer from arrhythmia in its most common form, Atrial Fibrillation (AFib). Patients with AFib face an estimated five-times higher risk of stroke and more than double their risk of Sudden Cardiac Death. Cardea SOLO is available by contacting firstname.lastname@example.org.
About Cardiac Insight, Inc.
Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. developer of advanced body-worn digital health care information systems through its proprietary software, algorithms and devices. The company’s two flagship products are its wearable ECG Sensor and Analysis Software System, Cardea SOLO™ (www.cardeasolo.com) and Cardea 20/20 ECG™, the only 12-lead test that incorporates the International Criteria for identification of the risk of Sudden Cardiac Arrest in young athletes. Founded in 2008, Cardiac Insight is an ISO-certified company and is based in Kirkland, Washington, USA.
Source: Cardiac Insight, Inc.